Gritstone bio, Inc.
NASDAQ: GRTS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew R. Allen BCh, BM, MA, MRCP,
- Employees
- 231
- Headquarters
- EmeryVille, United States
- IPO year
- 2018
- Market cap
- $3.8M
- Website
- https://gritstonebio.com
Loading GRTS…
Loading profile data…Frequently asked questions about GRTS
What does Gritstone bio, Inc. (GRTS) do?
Gritstone bio, Inc. is a clinical-stage biotechnology company focused on pioneering immunotherapies to address various types of cancer and infectious diseases. Its primary product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat a range of solid tumors, specifically including metastatic non-small cell lung cancer, gastro...
Where does GRTS trade?
Gritstone bio, Inc. (GRTS) trades on the NASDAQ Global Select.
What sector is GRTS in?
Gritstone bio, Inc. (GRTS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gritstone bio, Inc.?
Andrew R. Allen BCh, BM, MA, MRCP, is the chief executive officer of Gritstone bio, Inc. (GRTS).
Where is Gritstone bio, Inc. headquartered?
Gritstone bio, Inc. is headquartered in United States.
Does GRTS pay a dividend?
Gritstone bio, Inc. (GRTS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GRTS go public?
Gritstone bio, Inc. (GRTS) completed its initial public offering in 2018.